Women with osteoporosis have at least a 50% chance of reaching their target bone mineral density at 3 years if they have a ...

In the course of evaluating the optimal duration of bisphosphonate treatment the FDA found little benefit of treatment beyond 5 years. [1,2] Moreover, examination of studies where bisphosphonates ...

Alendronate has been shown to increase bone mineral density (BMD) and decrease fracture risk in postmenopausal women with osteoporosis, but the need for long-term treatment is unclear, especially ...